BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.8 CNY | +5.66% |
|
+1.66% | +5.14% |
| 05-07 | China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7% | MT |
| 05-07 | BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research, development and production of generic drugs and original new drugs. The Company's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The Company's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The Company mainly conducts its businesses in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.14% | 2.04B | |
| +32.18% | 694B | |
| +29.39% | 593B | |
| -1.38% | 371B | |
| +20.07% | 331B | |
| +7.23% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.45% | 169B |
- Stock Market
- Equities
- 688166 Stock
- News BrightGene Bio-Medical Technology Co., Ltd.
- Chinese Drug Regulator Certifies Two Drugs of BrightGene's Unit